Advances in non-dopaminergic pharmacological treatments of Parkinson's disease

Advances in non-dopaminergic pharmacological treatments of Parkinson's disease

Since the 1960’s treatments for Parkinson's disease (PD) have traditionally been directed to effectively restore or replace dopamine, with L-Dopa the gold standard. However, chronic L-Dopa use is associated with debilitating dyskinesias, limiting its effectiveness. This has created a need to de...

Full description

Bibliographic Details
Main Authors:	Sandy eStayte, Bryce eVissel
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2014-05-01
Series:	Frontiers in Neuroscience
Subjects:	Dopamine Dyskinesias Gene Therapy Therapeutics L-Dopa Parkinson's disease
Online Access:	http://journal.frontiersin.org/Journal/10.3389/fnins.2014.00113/full

Similar Items

Corrigendum: Advances in non-dopaminergic pharmacological treatments of Parkinson’s disease
by: Sandy eStayte, et al.
Published: (2014-08-01)

Targeting the cannabinoid receptor CB2 in a mouse model of l-dopa induced dyskinesia
by: Peggy Rentsch, et al.
Published: (2020-02-01)

Pharmacogenetics of antipsychotic-induced movement disorders as a resource for better understanding Parkinson's disease modifier genes
by: Lior eGreenbaum, et al.
Published: (2015-02-01)

Serotonergic and dopaminergic mechanisms in graft-induced dyskinesia in a rat model of Parkinson's disease
by: Eunju Shin, et al.
Published: (2012-09-01)

Influence of depressive symptoms on dopaminergic treatment of Parkinson’s disease
by: Alexandru eHanganu, et al.
Published: (2014-09-01)

Non-dopaminergic Alterations in Depression-Like FSL Rats in Experimental Parkinsonism and L-DOPA Responses
by: Nicoletta Schintu, et al.
Published: (2020-03-01)

The essential role of AMPA receptor GluR2 subunit RNA editing in the normal and diseased brain
by: Amanda Lorraine Wright, et al.
Published: (2012-04-01)

Time dependent degeneration of the nigrostriatal tract in mice with 6-OHDA lesioned medial forebrain bundle and the effect of activin A on l-Dopa induced dyskinesia
by: Peggy Rentsch, et al.
Published: (2019-02-01)

Role of 5-HT1A Receptor in Vilazodone-Mediated Suppression of L-DOPA-Induced Dyskinesia and Increased Responsiveness to Cortical Input in Striatal Medium Spiny Neurons in an Animal Model of Parkinson’s Disease
by: Feras Altwal, et al.
Published: (2021-09-01)

5-Hydroxy-tryptophan for the treatment of l-DOPA-induced dyskinesia in the rat Parkinson's disease model
by: Elisabetta Tronci, et al.
Published: (2013-12-01)

PT320, a Sustained-Release GLP-1 Receptor Agonist, Ameliorates L-DOPA-Induced Dyskinesia in a Mouse Model of Parkinson’s Disease
by: Tung-Tai Kuo, et al.
Published: (2023-02-01)

Behavioral effects of zonisamide on L-DOPA-induced dyskinesia in Parkinson's disease model mice
by: Hiromi Sano, et al.
Published: (2023-06-01)

Serotonin system implication in L-DOPA-induced dyskinesia: from animal models to clinical investigations
by: Manolo eCarta, et al.
Published: (2014-05-01)

Roles of the Functional Interaction between Brain Cholinergic and Dopaminergic Systems in the Pathogenesis and Treatment of Schizophrenia and Parkinson’s Disease
by: Srijan Acharya, et al.
Published: (2021-04-01)

Nicotine-mediated improvement in l-dopa-induced dyskinesias in MPTP-lesioned monkeys is dependent on dopamine nerve terminal function
by: Maryka Quik, et al.
Published: (2013-02-01)

Striatal inhibition of PKA prevents levodopa-induced behavioural and molecular changes in the hemiparkinsonian rat
by: Manon Lebel, et al.
Published: (2010-04-01)

Intrastriatal inhibition of aromatic amino acid decarboxylase prevents l-DOPA-induced dyskinesia: A bilateral reverse in vivo microdialysis study in 6-hydroxydopamine lesioned rats
by: Kerstin Buck, et al.
Published: (2008-02-01)

The management of orthostatic hypotension in Parkinson's disease
by: Alvaro eSanchez-Ferro, et al.
Published: (2013-06-01)

Adjuvant therapies for Parkinson’s disease: critical evaluation of safinamide
by: Stocchi F, et al.
Published: (2016-02-01)

7-Nitroindazole reduces L-DOPA-induced dyskinesias in non-human Parkinsonian primate
by: M. T. Herrero, et al.
Published: (2023-05-01)

Effects of L-dopa priming on cortical high beta and high gamma oscillatory activity in a rodent model of Parkinson's disease
by: Kristin B. Dupre, et al.
Published: (2016-02-01)

Dopamine-Depleted Dopamine Transporter Knockout (DDD) Mice: Dyskinesia with L-DOPA and Dopamine D1 Agonists
by: Vladimir M. Pogorelov, et al.
Published: (2023-11-01)

Prevention of L-Dopa-Induced Dyskinesias by MPEP Blockade of Metabotropic Glutamate Receptor 5 Is Associated with Reduced Inflammation in the Brain of Parkinsonian Monkeys
by: Marc Morissette, et al.
Published: (2022-02-01)

Transcriptome analysis in a rat model of l-DOPA-induced dyskinesia
by: Christine Konradi, et al.
Published: (2004-11-01)

Resveratrol Alleviates Levodopa-Induced Dyskinesia in Rats
by: Chang-Qing Zheng, et al.
Published: (2021-06-01)

Interaction between the 5-HT system and the basal ganglia: Functional implication and therapeutic perspective in Parkinson’s disease
by: Cristina eMiguelez, et al.
Published: (2014-03-01)

Cannabidiol as a Therapeutic Target: Evidence of its Neuroprotective and Neuromodulatory Function in Parkinson’s Disease
by: Felipe Patricio, et al.
Published: (2020-12-01)

Chronic 3,4-dihydroxyphenylalanine treatment induces dyskinesia in aphakia mice, a novel genetic model of Parkinson’s disease
by: Yunmin Ding, et al.
Published: (2007-07-01)

Corrigendum: Combination Treatment of Icariin and L-DOPA Against 6-OHDA-Lesioned Dopamine Neurotoxicity
by: Di-Sheng Lu, et al.
Published: (2020-10-01)

Pathophysiological Mechanisms and Experimental Pharmacotherapy for L-Dopa-Induced Dyskinesia
by: Fabbrini A, et al.
Published: (2021-04-01)

Early L-dopa, but not pramipexole, restores basal ganglia activity in partially 6-OHDA-lesioned rats
by: C. Marin, et al.
Published: (2014-04-01)

Combination Treatment of Icariin and L-DOPA Against 6-OHDA-Lesioned Dopamine Neurotoxicity
by: Di-Sheng Lu, et al.
Published: (2018-05-01)

The opioid agonist morphine decreases the dyskinetic response to dopaminergic agents in parkinsonian monkeys
by: Pershia Samadi, et al.
Published: (2004-06-01)

An Investigation of the Protective Effects of the Hydroalcoholic Extract of Persian Yellow Rose (Rosa foetida Herrm.) on Rats with Parkinson's Disease Induced by 6-Hydroxydopamine
by: Nahid Jivad*, et al.
Published: (2023-08-01)

Commentary: Evaluation of Models of Parkinson’s Disease
by: Patricia eMuñoz, et al.
Published: (2016-04-01)

Idiopathic Parkinson’s Disease, Osteoporosis, and Hip Fractures: A Case Report
by: Richard A. Rison, et al.
Published: (2011-01-01)

Lack of tolerance for the anti-dyskinetic effects of 7-nitroindazole, a neuronal nitric oxide synthase inhibitor, in rats
by: N. Novaretti, et al.
Published: (2010-11-01)

Dopamine D3 Receptor Plasticity in Parkinson’s Disease and L-DOPA-Induced Dyskinesia
by: Kathryn Lanza, et al.
Published: (2021-03-01)

Excessive sensitivity to uncertain visual input in L-dopa induced dyskinesias in Parkinson’s disease: further implications for cerebellar involvement
by: James eStevenson, et al.
Published: (2014-02-01)

Predictors of Freezing of Gait in Parkinson’s disease
by: Jacob eCrouse, et al.
Published: (2015-06-01)